Apr 10, 2023, 06:00 ET  Data expands upon previously reported results, including individual patient data, additional liver biomarkers, and comparisons to matching arms from a contemporaneous study Company on track to report data from ongoing Phase 2b AHFIRM trial in 2H 2023 CUPERTINO, Calif., April 10, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical […]

 Mar 21, 2023, 16:30 ET  CUPERTINO, Calif., March 21, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that Gail Maderis has assumed the role of Chair of the Board of DURECT effective March 17, 2023.  Ms. Maderis succeeds David Hoffmann as Chair of the Board. Mr. Hoffman has decided not to stand for re-election

 Mar 09, 2023, 08:30 ET  CUPERTINO, Calif., March 9, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James Brown, President and CEO and additional members of the management team will participate in a fireside chat hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer & Co. Inc. at the

 Mar 07, 2023, 16:05 ET  –  Webcast of Earnings Call Today, March 7th at 4:30 p.m. ET –  Topline data from AHFIRM trial expected in 2023 CUPERTINO, Calif., March 7, 2023 /PRNewswire / — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2022 and provided a

 Feb 28, 2023, 18:07 ET  CUPERTINO, Calif., Feb. 28, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and full year 2022 financial results and host a conference call after the market close on Tuesday, March 7, 2023. Tuesday, March 7 @ 4:30pm Eastern Time / 1:30pm Pacific

 Feb 03, 2023, 17:17 ET  CUPERTINO, Calif., Feb. 3, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) (“DURECT”), a biopharmaceutical company focused on developing its epigenetic regulator program for the treatment of acute organ injury and chronic liver diseases, today announced that it has entered into a definitive agreement with a leading institutional healthcare investor and

 Nov 28, 2022, 18:46 ET  CUPERTINO, Calif., Nov. 28, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ injury and chronic liver diseases, announced that DURECT’s board of directors today determined that the Company will effect a reverse stock split at a

 Nov 02, 2022, 16:05 ET  –  Webcast of Earnings Call Today, November 2nd at 4:30 p.m. ET –  AHFIRM trial timeline continues to improve CUPERTINO, Calif., Nov. 2, 2022 /PRNewswire / — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2022 and provided a corporate update. “We are

 Oct 26, 2022, 08:30 ET  CUPERTINO, Calif., Oct. 26, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will report its third quarter 2022 financial results and host a conference call after the market close on Wednesday, November 2, 2022. Wednesday, November 2 @ 4:30pm Eastern Time / 1:30pm Pacific Time Toll Free:

 Oct 06, 2022, 08:30 ET  AHFIRM enrollment surpasses 200 of the planned 300 AH patients Enrollment completion now anticipated in Q2 2023 CUPERTINO, Calif., Oct. 6, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ injury and chronic liver diseases, today announced